Perfusion Abnormalities in Hypertrophic Cardiomyopathy
Not yet recruiting
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Registration Number
- NCT06599229
- Lead Sponsor
- University of Virginia
- Brief Summary
The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Diagnosis of hypertrophic cardiomyopathy
- Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy
Exclusion Criteria
- Pregnancy
- Lactation
- Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
- Serious AE to regadenoson
- Hypotension
- Serious bradycardia not addressed by pacemaker
- Moderate or greater reactive airways disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Peak hyperemic perfusion 3 months Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)
- Secondary Outcome Measures
Name Time Method Resting myocardial perfusion 3 months Resting myocardial perfusion by MCE